TBPH Theravance Biopharma Inc

Price (delayed)

$16.38

Market cap

$844.44M

P/E Ratio

7.22

Dividend/share

N/A

EPS

$2.27

Enterprise value

$596.01M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 98

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to create transformational medicines to improve the lives ...

Highlights
The company's quick ratio has surged by 177% YoY and by 20% QoQ
TBPH's revenue has soared by 68% year-on-year and by 2.2% since the previous quarter
TBPH's equity has soared by 75% year-on-year but it is down by 2.1% since the previous quarter

Key stats

What are the main financial stats of TBPH

TBPH stock price

How has the Theravance Biopharma stock price performed over time
Intraday
2.89%
1 week
1.05%
1 month
-3.13%
1 year
48.77%
YTD
-12.45%
QTD
0.92%

Financial performance

How have Theravance Biopharma's revenue and profit performed over time
Revenue
$109.78M
Gross profit
$109.78M
Operating income
$1.35M
Net income
$114.54M
Gross margin
100%
Net margin
104.3%
The operating income has soared by 137% QoQ and by 103% YoY
Theravance Biopharma's operating margin has surged by 135% QoQ and by 102% YoY
TBPH's revenue has soared by 68% year-on-year and by 2.2% since the previous quarter
The gross profit has soared by 68% YoY and by 2.2% from the previous quarter

Price vs fundamentals

How does TBPH's price correlate with its fundamentals

Growth

What is Theravance Biopharma's growth rate over time

Valuation

What is Theravance Biopharma stock price valuation
P/E
7.22
P/B
2.9
P/S
7.65
EV/EBIT
4.3
EV/EBITDA
4.13
EV/Sales
5.43
TBPH's P/E is 67% below its last 4 quarters average of 21.3
Theravance Biopharma's EPS has increased by 8% QoQ
TBPH's equity has soared by 75% year-on-year but it is down by 2.1% since the previous quarter
The price to book (P/B) is 2.8% lower than the last 4 quarters average of 2.9
TBPH's revenue has soared by 68% year-on-year and by 2.2% since the previous quarter
The P/S is 28% lower than the 5-year quarterly average of 10.3 and 9% lower than the last 4 quarters average of 8.2

Efficiency

How efficient is Theravance Biopharma business performance
The ROIC has grown by 12% from the previous quarter
The ROE has contracted by 4.8% from the previous quarter
Theravance Biopharma's return on sales has increased by 3.1% QoQ

Dividends

What is TBPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TBPH.

Financial health

How did Theravance Biopharma financials performed over time
Theravance Biopharma's total assets is 160% more than its total liabilities
The company's quick ratio has surged by 177% YoY and by 20% QoQ
TBPH's current ratio has surged by 175% year-on-year and by 20% since the previous quarter
Theravance Biopharma's debt is 86% lower than its equity
TBPH's equity has soared by 75% year-on-year but it is down by 2.1% since the previous quarter
The debt to equity has shrunk by 52% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.